现代诊断与治疗
現代診斷與治療
현대진단여치료
Modern Diagnosis & Treatment
2015年
13期
2899-2902
,共4页
中医辨证%耐多药肺结核病%淋巴细胞亚群变化
中醫辨證%耐多藥肺結覈病%淋巴細胞亞群變化
중의변증%내다약폐결핵병%림파세포아군변화
TCM Differentiation%Multidrug-resistant Tuberculosis%lymphocyte Subsets Changes%Adverse reactions%Curative Effect
目的 分析中医辨证联合化疗方案治疗耐多药肺结核病(MDR-TB)疗效及安全性.方法 随机选取2011年1月~2014年1月我院收治的200例耐多药肺结核患者为研究对象,其中男112例,女88例,年龄22~71(42.7±3.3)岁.病程1~18(7.1±1.5)年.随机分为观察组与对照组各100例,采用两组全程给予莫西沙星治疗,对照组应用药物为8(D+Z+Pto+Am)/12(D+Z+Pto),观察组在对照组的基础上加用微卡,两组疗程均为20个月,比较两组治疗后2、4、6及12个月的痰菌阴转率;胸片检查病灶吸收情况及CD3+、CD4+、CD8+ 淋巴CD4+/CD8+细胞亚群变化和患者不良反应情况.结果 (1)观察组患者治疗后2、4、6及12月的痰菌阴转率[分别为37(37%)、62(62%)、75(75%)、 77(77%)]与对照组[分别为(19(19%)、42(42%)、51(51%)、52 (52%)]比较,差异均有统计学意义(P<0.05;P<0.01);(2)观察组病灶显著吸收、吸收、无变化的有效率与对照组比较,差异均有统计学意义(P<0.05);(3)观察组CD3+、CD4+、CD8+、 CD4+/CD8+淋巴细胞亚群变化与对照组比较,差异均有统计学意义(P<0.05);(4)两组不良反应发生率比较,差异均无统计学意义(P>0.05).结论 中医辨证联合化疗方治疗MDR-TB,可以提高临床痰菌转阴率,有助于病灶吸收,改善提高患者免疫力,同时不增加临床不良反应,安全有效.
目的 分析中醫辨證聯閤化療方案治療耐多藥肺結覈病(MDR-TB)療效及安全性.方法 隨機選取2011年1月~2014年1月我院收治的200例耐多藥肺結覈患者為研究對象,其中男112例,女88例,年齡22~71(42.7±3.3)歲.病程1~18(7.1±1.5)年.隨機分為觀察組與對照組各100例,採用兩組全程給予莫西沙星治療,對照組應用藥物為8(D+Z+Pto+Am)/12(D+Z+Pto),觀察組在對照組的基礎上加用微卡,兩組療程均為20箇月,比較兩組治療後2、4、6及12箇月的痰菌陰轉率;胸片檢查病竈吸收情況及CD3+、CD4+、CD8+ 淋巴CD4+/CD8+細胞亞群變化和患者不良反應情況.結果 (1)觀察組患者治療後2、4、6及12月的痰菌陰轉率[分彆為37(37%)、62(62%)、75(75%)、 77(77%)]與對照組[分彆為(19(19%)、42(42%)、51(51%)、52 (52%)]比較,差異均有統計學意義(P<0.05;P<0.01);(2)觀察組病竈顯著吸收、吸收、無變化的有效率與對照組比較,差異均有統計學意義(P<0.05);(3)觀察組CD3+、CD4+、CD8+、 CD4+/CD8+淋巴細胞亞群變化與對照組比較,差異均有統計學意義(P<0.05);(4)兩組不良反應髮生率比較,差異均無統計學意義(P>0.05).結論 中醫辨證聯閤化療方治療MDR-TB,可以提高臨床痰菌轉陰率,有助于病竈吸收,改善提高患者免疫力,同時不增加臨床不良反應,安全有效.
목적 분석중의변증연합화료방안치료내다약폐결핵병(MDR-TB)료효급안전성.방법 수궤선취2011년1월~2014년1월아원수치적200례내다약폐결핵환자위연구대상,기중남112례,녀88례,년령22~71(42.7±3.3)세.병정1~18(7.1±1.5)년.수궤분위관찰조여대조조각100례,채용량조전정급여막서사성치료,대조조응용약물위8(D+Z+Pto+Am)/12(D+Z+Pto),관찰조재대조조적기출상가용미잡,량조료정균위20개월,비교량조치료후2、4、6급12개월적담균음전솔;흉편검사병조흡수정황급CD3+、CD4+、CD8+ 림파CD4+/CD8+세포아군변화화환자불량반응정황.결과 (1)관찰조환자치료후2、4、6급12월적담균음전솔[분별위37(37%)、62(62%)、75(75%)、 77(77%)]여대조조[분별위(19(19%)、42(42%)、51(51%)、52 (52%)]비교,차이균유통계학의의(P<0.05;P<0.01);(2)관찰조병조현저흡수、흡수、무변화적유효솔여대조조비교,차이균유통계학의의(P<0.05);(3)관찰조CD3+、CD4+、CD8+、 CD4+/CD8+림파세포아군변화여대조조비교,차이균유통계학의의(P<0.05);(4)량조불량반응발생솔비교,차이균무통계학의의(P>0.05).결론 중의변증연합화료방치료MDR-TB,가이제고림상담균전음솔,유조우병조흡수,개선제고환자면역력,동시불증가림상불량반응,안전유효.
Objective To analyze the efficacy and safety of TCM syndrome differentiation combined with chemotherapy in the treatment of multi drug resistant pulmonary tuberculosis (MDR-TB). Methods Randomly selected from January 2011 to January 2014, 200 patients with multi drug resistant pulmonary tuberculosis were studied,including 112 males and 88 females,aged from 22 to 71 (42.7±3.3) years. The course of disease was from 1 to 18 (7.1±1.5) years. Randomly divided into observation group and control group with 100 cases in each. The two groups given a full course of moxifloxacin in the treatment of,the group using drugs control 8 D+Z+Pto+Am / D+Z+Pto. Observation group on the basis of the control group treated with micro card. The course of treatment in the two groups were 20 months and compared between the two groups after treatment 2,4,6 and 12 months of sputum Yin conversion rate;chest lesions absorption and CD3+, CD4+,CD8+ lymphocyte CD4+ / CD8+ cell subsets change and adverse reaction in the patients of the situation.Results (1)In the observation group, 2, 4, 6 and December were compared with the control group (19 (37%), 62 (75%), 77 (77%), 51 (19%), 42 (51%), 52 (52%), respectively, and the difference was statistically significant (P< 0.05,P<0.01);(2)In the observation group, the difference was statistically significant (P<0.05);(3) CD3+, CD8+, CD4+ and CD4+/CD8+ lymphocyte subsets in the observation group were significantly different from the control group (P<0.05);(4)There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusions TCM combined with chemotherapy Decoction "in the treatment of MDR-TB can improve clinical sputum negative conversion rate, helps in the absorption of lesions, improve the immunity of the patients, and no adverse reaction, safe and effective.
